Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
707 A Phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, in patients with mesothelin expressing solid cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.